Evidence map›Paper›PMID 32789747›Full record

ArticleCerebellum (London, England)2021

Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel-Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3.

David D Bushart, Annie J Zalon, Hongjiu Zhang, Logan M Morrison, Yuanfang Guan, Henry L Paulson, Vikram G Shakkottai, Hayley S McLoughlin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cerebellum (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Identification of the Prodromal Symptoms and Pre-Ataxic Stage in Cerebellar Disorders: The Next Challenge.International journal of environmental research and public health · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

David D Bushart *Department of Neurology, University of Michigan, 109 Zina Pitcher Pl., Ann Arbor, MI, 48109, USA.
Annie J Zalon *Department of Neurology, University of Michigan, 109 Zina Pitcher Pl., Ann Arbor, MI, 48109, USA.
Hongjiu ZhangDepartment of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.
Logan M MorrisonDepartment of Neurology, University of Michigan, 109 Zina Pitcher Pl., Ann Arbor, MI, 48109, USA.
Yuanfang GuanDepartment of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.
Henry L PaulsonDepartment of Neurology, University of Michigan, 109 Zina Pitcher Pl., Ann Arbor, MI, 48109, USA.
Vikram G ShakkottaiDepartment of Neurology, University of Michigan, 109 Zina Pitcher Pl., Ann Arbor, MI, 48109, USA. vikramsh@med.umich.edu.
Hayley S McLoughlinDepartment of Neurology, University of Michigan, 109 Zina Pitcher Pl., Ann Arbor, MI, 48109, USA. hayleymc@med.umich.edu.ORCID http://orcid.org/0000-0003-4279-2758
University of Michigan · USMicrosoft (United States) · US

Funding

Mechanisms of Polyglutamine NeurodegenerationR01NS038712 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PAULSON, HENRY L · 2000 to 2019
$8.1M
Mechanisms of neurodegenerative diseases: intersections with ubiquitin pathwaysR35NS122302 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Henry L Paulson · 2021 to 2026
$6.4M
Identifying symptomatic and neuroprotective strategies for cerebellar ataxiaR01NS085054 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI SHAKKOTTAI, VIKRAM GOVINDARAJU · 2013 to 2023
$4.3M
Preclinical Development of Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 3U01NS106670 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCLOUGHLIN, HAYLEY SARAH, PAULSON, HENRY L · 2018 to 2021
$2.1M
NINDS NIH HHS R01 NS038712NINDS NIH HHS R01 NS085054NINDS NIH HHS R01-NS085054NINDS NIH HHS R35 NS122302NINDS NIH HHS U01 NS106670NINDS NIH HHS U01-NS106670
6 · The paper itself

Abstract

Spinocerebellar ataxia type 3 (SCA3) is the second-most common CAG repeat disease, caused by a glutamine-encoding expansion in the ATXN3 protein. SCA3 is characterized by spinocerebellar degeneration leading to progressive motor incoordination and early death. Previous studies suggest that potassium channel dysfunction underlies early abnormalities in cerebellar cortical Purkinje neuron firing in SCA3. However, cerebellar cortical degeneration is often modest both in the human disease and mouse models of SCA3, raising uncertainty about the role of cerebellar dysfunction in SCA3. Here, we address this question by investigating Purkinje neuron excitability in SCA3. In early-stage SCA3 mice, we confirm a previously identified increase in excitability of cerebellar Purkinje neurons and associate this excitability with reduced transcripts of two voltage-gated potassium (K

Indexed as

AnimalsAtaxin-3Behavior, AnimalHumansInjections, IntraventricularKv1.6 Potassium ChannelMachado-Joseph DiseaseMiceMice, TransgenicOligonucleotides, AntisensePatch-Clamp TechniquesPhenotypePotassium Channels, Voltage-GatedPurkinje CellsRepressor ProteinsShaw Potassium ChannelsAtaxin-3ATXN3 protein, humanKCNA6 protein, humanKCNC3 protein, humanKv1.6 Potassium ChannelOligonucleotides, AntisensePotassium Channels, Voltage-GatedRepressor ProteinsShaw Potassium ChannelsAntisense oligonucleotideAtaxiaCerebellumPotassium channelPurkinje neuron

Identifiers

PMID32789747
PMCPMC7930886
OpenAlexW3048633694

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.